Xilio reports 26% ORR for vilastobart+atezo in MSS CRC without liver mets; plans to partner program

Xilio Therapeutics, Inc.

26% ORR (7 PRs, 6 confirmed) in 27 MSS CRC patients without liver metastases; responses ongoing up to 37 weeks.
Differentiated safety: only 7% colitis (3/44), low discontinuation (5%); combination well-tolerated.
Patient with liver metastasis from Phase 1C on treatment >14 months; 150mg Q6W dose cleared and cohort enrolling.
Xilio seeking partnership for vilastobart to accelerate development; additional data expected H1 2026.

item 7.01item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.